The inexpensive anti-malarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen, a widely used breast cancer drug, in mice.
In the June 15 issue of Clinical Cancer Research, investigators from Georgetown Lombardi Comprehensive Cancer Center say adding HCQ to tamoxifen could provide a new treatment option for some women with advanced, postmenopausal estrogen receptor-positive (ER+) breast cancer. The ER+ subtype accounts for an estimated 70 percent of all breast cancers. While many of these women are treated with tamoxifen, which blocks estrogen from fueling the tumor, 50 percent of these cancers will either not respond or will become resistant to tamoxifen over time.
"Tamoxifen resistance when treating breast cancer is a big issue in the clinic, and we believe our findings provide a very promising fix to the problem," says the study's senior investigator, Robert Clarke, PhD, DSc, dean for research at Georgetown University Medical center, and co-director of the breast cancer program at Georgetown Lombardi.
Clarke adds that both drugs are inexpensive, on the market and have a well-defined safety profile.
HCQ was developed to treat malaria, but has since been repurposed as therapy for rheumatoid arthritis and lupus. The study is the first to test HCQ's ability to restore breast cancer cell sensitivity to tamoxifen or to a different anti-estrogen drug known as faslodex.
The research team, led by first author Katherine Cook, PhD, a postdoctoral research fellow in the tumor biology department at Georgetown Lombardi, purposely set out to test HCQ in mice with either tamoxifen or faslodex-resistant human breast cancer cells.
Previous research led by Clarke and Cook found that tamoxifen resistance occurs because a pro-survival pathway is switched on in breast cancer cells. HCQ functions by turning off that very same molecular pathway, Cook says.
The researchers found that the combination of tamoxifen and HCQ is more effective than faslodex and HCQ due to activities within the tumor's microenvironment. "Faslodex and tamoxifen, while both effective as antiestrogen therapies, have different effects on the immune system thus making the combination of faslodex and HCQ less effective," says Cook.
"Many people have been trying combinations of drugs to restore the ability of tamoxifen to fight breast cancer. We believe this pairing is very worthy of additional research, as well as clinical study," she says.
The study is supported by a Department of Defense Breast Cancer Research Program Postdoctoral Fellowship (BC112023) and awards from the US Department of Health and Human Services (R01-CA131465 and U54-CA149147).
The authors have no conflicts of interest.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and MedStar Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 41 comprehensive cancer centers in the nation, as designated by the National Cancer Institute (grant #P30 CA051008), and the only one in the Washington, DC area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.
Karen Teber | Eurek Alert!
'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS
New process allows tailor-made malaria research
16.02.2018 | Eberhard Karls Universität Tübingen
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
16.02.2018 | Information Technology
16.02.2018 | Health and Medicine
16.02.2018 | Physics and Astronomy